Avadel Pharma (AVDL) announces favorable ruling in LUMRYZ case
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- US stock index futures slip as high-stakes Iran, inflation tests loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction
May 6, 2025 12:30 PM EDT- With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia -
- Federal Circuit decision permits new clinical trials and further development of LUMRYZÂ for the treatment of indications beyond narcolepsy -
DUBLIN, Ireland, May 06, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that the United States Court of Appeals for the Federal Circuit (the Federal Circuit) has ruled in favor of... More
